An office and event space nestled within a multistorey carpark in Basel’s rapidly growing innovation district forms an ...

Creating a workspace that inspires employees to be productive and motivated is essential for any organization aiming to improve performance. The relationship between office design and the interactions ...

Two of Cytiva’s top executives offer updates on the company's $1.6 billion in expansion projects worldwide, all to meet growing market demand for its services from developers and manufacturers of ...

A new survey suggests it’s time to go beyond the generic workplace look some call 'the beige box of despair' and hang some ...

With hybrid lifestyles now the norm, business trips have become more intentional, more mobile, and surprisingly more ...

Anne Wojcicki's nonprofit, TTAM Research Institute, has received court approval to acquire 23andMe, the genetic testing ...

Regeneron launches a $200 million matching donation program for Good Days’ Retinal Disease Fund to enhance patient access to medicines.

23andMe is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, casting doubt on its deal with Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Overall, this quarter could have been better. Regeneron is down 31.4% since the beginning of the year, and at $490.50 per share, it is trading 59.2% below its 52-week high of $1,202 from August 2024.